Genmab A/S Cash Flow Statement
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Genmab A/S free cash flow
In fiscal 2025, Genmab A/S generated $1.19 billion of operating cash flow and spent $37.0 million on capital expenditures. That left free cash flow of $1.15 billion, a free-cash-flow margin of 30.9% of revenue. Free cash flow was up 4.5% from the prior year's $1.10 billion.
Summary generated from market data by MetaCap's automated system. Methodology
Genmab A/S cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | 963.00M | 1.13B | 631.00M |
| Net Income growth (YoY) | -15.00% | +79.56% | — |
| Stock-Based Compensation | 128.00M | 105.00M | 85.00M |
| Operating Cash Flow | 1.19B | 1.13B | 1.07B |
| Capital Expenditures | -37.00M | -27.00M | -53.00M |
| Investing Cash Flow | -5.64B | -1.45B | -185.00M |
| Debt Issued | 5.50B | 0 | 0 |
| Debt Repaid | -273.00M | 0 | 0 |
| Financing Cash Flow | 4.79B | -566.00M | -89.00M |
| Free Cash Flow | 1.15B | 1.10B | 1.02B |
This table shows 3 annual periods of Genmab A/S's cash flow statement, from FY 2025 back to FY 2023, across 9 line items including net income, stock-based compensation, operating cash flow. Values in USD; B = billions, M = millions. Fiscal periods follow GMAB's reporting calendar. What is a cash flow statement?